VIVE:NASDAQ

Viveve Medical Inc.

Viveve, Inc. is a women's health company committed to enhancing women’s lives by providing clinically proven, high quality products that improve their overall well-being and quality of life.
The globally patented Viveve® System, that delivers the GENEVEVE™ treatment, remodels and restores vaginal collagen using cryogen-cooled, monopolar radiofrequency (CMRF) energy-based technology in a single 30-minute out-patient session.
International regulatory clearances have been received for vaginal laxity and/or improvement in sexual function indications from over 50 countries. Consistent with these approvals, Viveve has submitted an IDE to the FDA to conduct a pivotal study on use of the device for improvement in sexual function. Currently, in the United States, the Viveve System is cleared by the FDA for general surgical procedures for electrocoagulation and hemostasis.
InControl Products by Viveve are FDA cleared medical devices that treat stress, urge, and mixed incontinence conditions and products to improve pelvic floor strength. Viveve exclusively distributes InControl Medical’s products to healthcare providers in the United States.
VIVE:NASDAQ

Expert Comments:

Brian Marckx, Zacks Small-Cap Research (11/15/17)
"The 47 U.S. consoles that Viveve Medical Inc. placed in Q3/17 was, by far, the strongest since the domestic launch in Q4/16 and up from 27 in Q2/17 and 29 in Q1/17. The company will build on this early momentum in the U.S. and expects to incrementally increase the size of the sales force, including adding reps during the remainder of 2017." -Zacks Small-Cap Research

Anthony Vendetti, Maxim Group (11/9/17)
"Viveve Medical Inc.'s Q3/17 revenue of $4.07M, up 120% year over year, was in line with the preannouncement and our estimate of $4.1M and above consensus of $3.71M. . .the company increased the low end of its FY17 revenue guidance to a range of $15–16M, from $14–16M. . .we would continue to be buyers of Viveve after it reported in line Q3/17 results and tweaked 2017 revenue guidance upward."

Jeff Cohen, Ladenburg Thalmann (11/9/17)
"Viveve Medical Inc. announced Q3/17 revenue of $4.1M. . .[it] increased 120% on an annual basis and 32% sequentially as the company's commercial and clinical activities continue to drive adoption and penetration in the marketplace, particularly in the United States. Viveve raised its outlook for 2017 revenues from $14M to the $15–16M range."

Maxim Group reported on this firm's Q3/17 earnings, as well as its progress in obtaining international regulatory clearances for its medical system.
read more >
Brian Marckx, Zacks Small-Cap Research (10/20/17)
"Viveve Medical Inc.'s Q3/17 revenue, expected to come in at approximately $4.1M, compares to our $3.7M estimate. Meanwhile, the company expects to report that there were 60 consoles (geographic breakdown not disclosed) placed and about 2,700 treatment tips sold compared to our 60 (26 U.S., 34 international) and 2,900 estimates." -Zacks Small-Cap Research

Anthony Vendetti, Maxim Group (10/18/17)
"Today, before the market open, Viveve Medical Inc. announced preliminary Q3/17 revenue of approximately $4.1M, up roughly 122% year over year, relatively in line with our estimate of $4.2M and above consensus of $3.7M. Sixty Geneveve systems shipped in Q3/17, bringing the total commercial installed base to 364 systems; the company also sold approximately 2,700 consumable treatment tips in the quarter."

Brian Marckx, Zacks Equity Research (8/21/17)
"One of the major operational items of interest since Viveve Medical Inc.'s Q1 update is an agreement with InControl Medical LLC (ICM). . .for VIVE to serve as exclusive distributor of that company's innovative incontinence therapy devices to U.S. healthcare providers. . .ICM's products are the same as VIVE's existing target customers. . .ICM's products should provide a relatively seamless add-to-the-bag opportunity for Viveve's direct reps. . .management further commented that results of the ex vivo study were extremely good , that their meeting with FDA was very successful and that they believe their preclinical protocol will be acceptable by FDA."

Brian Marckx, analyst with Zacks Small-Cap Research, reports that a $20 million loan received by a U.S.-based medical device company could further fuel growth.
read more >

More Expert Comments

Experts Following This Company

Gregory Chodaczek, Analyst – Sterne Agee
Jeff Cohen, Analyst – Ladenburg Thalmann
Josh Jennings – Cowen & Co.
Brian Marckx, CFA – Zacks Small-Cap Research
Anthony Vendetti – Maxim Group

The information provided above is from analysts, newsletters, the company and other contributors.

Viveve Medical Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
First clinically efficacious technology addressing a $7B market opportunity with limited to no competition
 
Seasoned medical device executive team with a history of significant successes
 
Highly undervalued stock with >90% ownership from high quality, institutional healthcare investors